Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1BIIB019 (Daclizumab High Yield Process)
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
2BIIB019 (Daclizumab)
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
3CHOP-daclizumab
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 26 💬
4Daclizumab
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬10件: 13, 26, 56, 60, 63, 65, 97, 107, 283, 284 💬
5Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
6Daclizumab High Yield Process
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
7DACLIZUMAB HYP
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
8Daclizumab HYP (DAC HYP
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
9Daclizumab HYP (DAC HYP)
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
10DACLIZUMAB HYPProduct Code: BIIB019Pharmaceutical Form: Solution for injectionINN or Proposed INN: Daclizumab wih Greek suffixCurrent Sponsor code: BIIB019Other descriptive name: Daclizumab HYP (DAC HYP)Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 150-Pharmaceutical form of the placebo: Solution for injectionRoute of administration of the placebo: Subcutaneous use
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
11Daclizumab with Greek suufix
(D03639)		1件: Daclizumab1件: Daclizumab (D03639) 💬 1件: IL2RA 💬 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬